Skip to main content

Pagaya Technologies Ltd.

For the period ended Jun 30, 2025. Filed Aug 7, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Jun 30, 2025 · Filed Aug 7, 2025

PGY$17.21-5.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)

(In thousands)

Six Months Ended June 30,
20252024
Cash flows from operating activities
Net income (loss) including noncontrolling interests$19,055$(114,341)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Equity method loss (income)2,446(86)
Depreciation and amortization15,31513,359
Share-based compensation31,40033,519
Fair value adjustment to warrant liability1,578(1,571)
Impairment loss on investments in loans and securities, net (1)54,60580,046
Gain on sale of investments in loans and securities(8,690)—
Amortization of deferred costs5,8431,250
Write-off of capitalized software—2,561
Loss on foreign exchange1,311186
Change in operating assets and liabilities:
Fees and other receivables (1)(22,132)(11,614)
Accrued interest on investments (1)(15,246)(10,204)
Prepaid expenses and other assets9,628998
Right-of-use assets3,0353,879
Accounts payable2,1086,071
Accrued expenses and other liabilities(5,842)7,793
Operating lease liability(3,001)(3,205)
Income taxes36418,363
Net cash provided by operating activities91,77727,004
Cash flows from investing activities
Proceeds from the sale/maturity/prepayment of:
Investments in loans and securities (1)129,35075,779
Acquisition of Theorem Technology, Inc., net of cash acquired159—
Payments for the purchase of:
Investments in loans and securities(274,125)(408,459)
Property and equipment(7,576)(9,525)
Equity method and other investments—(125)
Net cash used in investing activities(152,192)(342,330)
Cash flows from financing activities
Proceeds from sale of ordinary shares, net of issuance costs—89,956
Proceeds from long-term debt—244,725
Proceeds from secured borrowing244,894207,317
Proceeds received from noncontrolling interests—2,815
Proceeds from revolving credit facility—44,000
Proceeds from exercise of stock options, warrants and contributions to ESPP3,977759
Proceeds from issuance of ordinary shares from the Equity Financing Purchase Agreement—5,338
Distributions made to noncontrolling interests(8,420)(5,318)
Payments made to revolving credit facility—(134,000)
Payments made to secured borrowing(156,924)(78,809)
Payments made to long-term debt(8,875)(6,375)
Debt issuance costs—(7,974)
Net cash provided by financing activities74,652362,434
Effect of exchange rate changes on cash, cash equivalents and restricted cash1,279(1,723)
Net increase in cash, cash equivalents and restricted cash15,51645,385
Cash, cash equivalents and restricted cash, beginning of period226,518222,541
Cash, cash equivalents and restricted cash, end of period$242,034$267,926
Reconciliation of cash, cash equivalents, and restricted cash within the unaudited condensed consolidated balance sheet to the amounts shown in the statements of cash flow above:
Cash and cash equivalents$182,986$233,593
Restricted cash - current23,84517,469
Restricted cash - non-current35,20316,864
Total cash, cash equivalents, and restricted cash$242,034$267,926

(1) Accrued interest receivable of $14.3 million, previously reported within “Fee and other receivables” as of December 31, 2024, has been reclassified to “Investment in loans and securities” to conform to the current period’s presentation and six month ended June 30, 2024 amounts have been reclassified to conform to the current period presentation.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.